Penn Medicine Provider
Medical Oncology
Peter J. O'Dwyer, MD
5.0
(48)
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West
Make an appointmentCall 215-615-5858

About me

  • Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia

Education and training

  • Medical School: University of Dublin Trinity College
  • Residency: Saint Patrick's Hospital and Health Sciences Center
  • Residency: Hammersmith Hospital
  • Residency: The Waterbury Hospital Health Center
  • Residency: Greater Baltimore Medical Center
  • Fellowship: University of Maryland Hospital
  • Fellowship: National Cancer Institute

What my patients think about me

Average Rating
5.0

48 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

March 2025
5.0
5.0
excellent dr
February 2025
5.0
5.0
already have recommended
January 2025
5.0
5.0
again, very thorough and helpful.
January 2025
5.0
5.0
very professional and knowledgeable

Insurance accepted

My Locations

Learn about location

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: On the medical staff, but does not have privileges to treat patients in the hospital.
Dr. O'Dwyer is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Shirao K, Hoff PM, Ohtsu A, Loehrer PJ, Hyodo I, Wadler S, Wadleigh RG, O’Dwyer PJ, Muro K, Yamada Y, Boku N, Nagashima F, Abbruzzese JL Comparison between the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur plus oral leucovorin regimen in Japanese and American patients with advanced colorectal cancer: joint USA and Japan study of UFT/LV , : 2003

Flaherty KT, Stevenson JP, Hahn SM, Redlinger M, O’Dwyer PJ Dose escalation and safety study of gemcitabine, carboplatin, and paclitaxel in patients with adavanced malignancy , Cancer Chemother Pharmacol: 2003

Giantonio BJ, Derry C, McAleer C, McPhillips JJ, O’Dwyer PJ Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly 2-hour infusion in patients with advanced solid tumors , : 2003

Yao KS, O’Dwyer PJ Role of the AP-1 element in mediating transcriptional induction of DT-diaphorase gene expression by oltipraz: a target for chemoprevention , Biochem Pharmacol: 2003

Schaner ME, Ross DT, Ciaravino G, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu I-P, Hernandez-Boussard T, Johnson SW, O’Dwyer PJ, Fero M, Kristensen GB, Borresen-Dale A-L, Hastie T, Tibshirani R, van de Rijn M, Teng NN, Longacre TA, Botstein D, Brown PO, Sikic BI Gene expression patterns in epithelial ovarian carcinomas , : 2003

Flaherty KT, O'Dwyer PJ Phase II trials in oncology , Anticancer Drug Development Guide: 2003

Vasilevskaya I, O’Dwyer PJ Role of Jun and Jun kinase (JNK) in resistance of cancer cells to therapy , Drug Resistance Updates: 2003

O’Dwyer PJ, Johnson SW Current status of oxaliplatin in colorectal cancer , Semin Oncol, 30(3 Supp 6): 2003,78-87

Bilenker JH, Stevenson JP, Flaherty KT, Algazy K, McLaughlin K, Haller DG, Giantonio BJ, Garcia-Vargas JE, O’Dwyer PJ Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies , : 2003

Veronese ML, Stevenson JP, Sun W, Redlinger M, Algazy K, Giantonio BJ, Hahn S, Vaughn D, Haller DG, O’Dwyer PJ Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer , : 2003